Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenhui Lou

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5031608841. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 5 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 5 papers · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 26

  1. M1 Macrophage-derived TNF-α Promotes Pancreatic Cancer Ferroptosis via p38 MAPK-ACSL4 Pathway. Co-author DOI 10.2174/0115665240374551250630075409↗
  2. Pancreatic surgery is safe in elderly patients with PDAC. Last author DOI 10.1186/s12877-025-05907-8↗
  3. Identification of methylation driver genes for predicting the prognosis of pancreatic cancer patients based on whole-genome DNA methylation sequencing technolo… Co-author DOI 10.1016/j.heliyon.2024.e29914↗
  4. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
  5. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Last author DOI 10.1016/j.bbcan.2022.188751↗
  6. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01384-3↗
  7. [Ten directions for improving clinical therapeutic effect of pancreatic cancer in the future]. Last author DOI 10.3760/cma.j.cn112139-20211109-00525↗
  8. [Pancreas multidisciplinary team optimizes the diagnosis and treatment of pancreas-related diseases and improves the prognosis of pancreatic cancer patients]. Co-author DOI 10.3760/cma.j.cn112139-20220408-00149↗
  9. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  10. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  11. DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Last author DOI 10.1111/jcmm.16196↗
  12. Author Correction: PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Last author DOI 10.1007/s13402-019-00480-w↗
  13. piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0486-z↗
  14. Author Correction: piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. Co-author DOI 10.1038/s41556-020-0520-1↗
  15. Correction: KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis Co-author DOI 10.1158/0008-5472.can-20-2503↗
  16. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Co-author DOI 10.1177/1758835920953728↗
  17. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗
  18. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pa… Co-author DOI 10.1007/s00262-015-1775-4↗
  19. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Last author DOI 10.1097/mpa.0000000000000501↗
  20. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. Last author DOI 10.1097/mpa.0000000000000520↗
  21. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Co-author DOI 10.1158/0008-5472.can-15-0671↗
  22. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Co-author DOI 10.18632/oncotarget.10630↗
  23. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.4506↗
  24. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-… Co-author DOI 10.7314/apjcp.2014.15.24.10647↗
  25. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. Co-author DOI 10.1007/s00268-013-2009-6↗
  26. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Last author DOI 10.1007/s13277-013-0679-1↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yefei Rong · 10 shared papers, 2013–2023 · strength 1.07
  2. Dansong Wang · 9 shared papers, 2013–2025 · strength 1.02
  3. Wenchuan Wu · 7 shared papers, 2013–2026 · strength 0.97
  4. Tiantao Kuang · 5 shared papers, 2013–2023 · strength 0.62
  5. Liang Liu · 2 shared papers, 2022–2025 · strength 0.47
  6. Lei Zhang · 2 shared papers, 2023–2025 · strength 0.44
  7. Xu Han · 5 shared papers, 2015–2021 · strength 0.44
  8. Wenquan Wang · 2 shared papers, 2022–2024 · strength 0.43
  9. Dayong Jin · 6 shared papers, 2013–2022 · strength 0.43
  10. Ning Pu · 2 shared papers, 2020–2026 · strength 0.43
  11. Hanlin Yin · 2 shared papers, 2020–2026 · strength 0.43
  12. Xuefeng Xu · 3 shared papers, 2016–2023 · strength 0.41
  13. L Liu · 2 shared papers, 2022 · strength 0.38
  14. Jianang Li · 3 shared papers, 2016–2023 · strength 0.37
  15. Weilin Mao · 2 shared papers, 2022–2023 · strength 0.34
  16. Jicheng Zhang · 1 shared paper, 2026 · strength 0.33
  17. Yaolin Xu · 2 shared papers, 2018–2025 · strength 0.32
  18. Mengmeng Liu · 2 shared papers, 2020–2024 · strength 0.32
  19. Chao Song · 2 shared papers, 2020–2024 · strength 0.32
  20. Yingbin Liu · 3 shared papers, 2020 · strength 0.29
  21. Peng Yuan · 3 shared papers, 2020 · strength 0.29
  22. Mo‐Fang Liu · 3 shared papers, 2020 · strength 0.29
  23. Hexige Saiyin · 3 shared papers, 2015–2021 · strength 0.25
  24. Yueming Zhang · 1 shared paper, 2025 · strength 0.25
  25. Zhihang Xu · 1 shared paper, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.